Your browser doesn't support javascript.
loading
Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro, Maria Julia; Palomo, Laura; Haferlach, Claudia; Acha, Pamela; Chan, Onyee; Navarro, Víctor; Kubota, Yasuo; Schulz, Felicitas Isabel; Meggendorfer, Manja; Briski, Robert; Al-Ali, Najla; Xicoy, Blanca; Lopez, Felix; Bosch, Francesc; González, Teresa; Eder, Lea Naomi; Jerez, Andrés; Wang, Yu-Hung Hung; Campagna, Alessia; Santini, Valeria; Bernal Del Castillo, Teresa; Such, Esperanza; Tien, Hwei-Fang; Díaz Varela, Nicolás; Platzbecker, Uwe; Haase, Detlef Thomas; Díez-Campelo, María; Della Porta, Matteo Giovanni; Garcia-Manero, Guillermo; Wiseman, Daniel Howard; Germing, Ulrich; Maciejewski, Jaroslaw P; Komrokji, Rami S; Sole, Francesc; Haferlach, Torsten; Valcárcel, David.
Afiliación
  • Montoro MJ; Department of hematology, University Hospital Vall d´Hebron, Barcelona, BARCELONA, Spain.
  • Palomo L; Institut Catala d'Oncololgia, Badalona, Spain.
  • Haferlach C; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Acha P; Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Chan O; Moffitt Cancer Center, Tampa, Florida, United States.
  • Navarro V; Vall d'hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Kubota Y; The University of Tokyo Hospital, Tokyo, Japan.
  • Schulz FI; Universitätsklinikum Düsseldorf, Düsseldorf, Germany.
  • Meggendorfer M; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Briski R; University of Texas MD Anderson Cancer Center, Houston, Texas, Houston, Texas, United States.
  • Al-Ali N; H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
  • Xicoy B; Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Barcelona, Spain.
  • Lopez F; Hospital del Mar, Barcelona, Spain.
  • Bosch F; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • González T; University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center, Department of Hematology Hospital Universitario de Salamanca, Salamanca, Spain.
  • Eder LN; University of Goettingen, Goettingen, Germany.
  • Jerez A; Hospital Morales Meseguer, Murcia, Spain.
  • Wang YH; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Campagna A; IRCCS Humanitas Research Hospital & Humanitas University, Rozzano - Milan, Italy.
  • Santini V; MDS Unit, University of Florence, Florence, Italy.
  • Bernal Del Castillo T; Hospital Central de Asturia, ISPA, IUOPAs, Oviedo, Spain.
  • Such E; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Tien HF; National Taiwan University Hospital, Taipei, Taiwan.
  • Díaz Varela N; Hospital Central de Asturia, ISPA, IUOPAs, oviedo, Spain.
  • Platzbecker U; University Hospital Leipzig, Department of Hematology and Cell Therapy, Leipzig, Germany.
  • Haase DT; University of Goettingen, Goettingen, Germany.
  • Díez-Campelo M; COMPLEJO ASISTENCIAL UNIVERSITARIO DE SALAMANCA, Salamanca, Spain.
  • Della Porta MG; IRCCS Humanitas Research Hospital & Humanitas University, Rozzano - Milan, Italy.
  • Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
  • Wiseman DH; The University of Manchester, Manchester, United Kingdom.
  • Germing U; Heinrich-Heine-University, Duesseldorf, Germany.
  • Maciejewski JP; Cleveland Clinic, Cleveland, Ohio, United States.
  • Komrokji RS; H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
  • Sole F; Institut de Recerca contra la Leucemia Josep Carreras. Barcelona, Spain, Badalona, Spain.
  • Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Valcárcel D; Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Blood ; 2024 Jul 29.
Article en En | MEDLINE | ID: mdl-39074355
ABSTRACT
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, while the remaining patients displayed monoallelic mutations. TP53 multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53 monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53 monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53 multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q).

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article País de afiliación: España